Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
EDITORIAL
Javier S Cabrera-Perez, Philippe Eigenmann, Ayobami Akenroye
No abstract text is available yet for this article.
April 2024: Pediatric Allergy and Immunology
#2
EDITORIAL
Clive E H Grattan, Emek Kocatürk
No abstract text is available yet for this article.
April 22, 2024: British Journal of Dermatology
#3
JOURNAL ARTICLE
Mustafa Ilker Inan, Yasemin Akgul Balaban
No abstract text is available yet for this article.
April 2024: Clinical Case Reports
#4
REVIEW
Rini Patadia, Thomas B Casale, John Fowler, Shiven Patel, Juan Carlos Cardet
INTRODUCTION: Asthma encompasses a spectrum of phenotypes often categorized into two groups- type 2 high (T2 high) and type 2 low (T2 low). T2 high includes atopic and eosinophilic presentations whereas T2 low is non-atopic, non-eosinophilic, and oft associated with neutrophilic inflammation. Eosinophilic asthma is often driven by IgE, IL-4, IL-5, and IL-13 and TSLP. This can lead to eosinophilic inflammatory response in the airways which in turn can be used as target for treatment. AREAS COVERED: The article will focus on biologic therapy that is currently being used in eosinophilic asthma management in mainly the adult population including clinical trials and co-morbidities that can be treated using the same biologics...
April 15, 2024: Expert Opinion on Biological Therapy
#5
JOURNAL ARTICLE
Tham T Le, Benjamin Emmanuel, Rohit Katial, Trung N Tran, Justin Joseph Kwiatek, David S Cohen, Shoshana R Daniel, Yunhui Cao, Vivian H Shih, Maria Gil Melcón, Gilles Devouassoux, Girolamo Pelaia
PURPOSE: Real-world evidence of benralizumab effectiveness on nasal polyps (NP) and asthma outcomes in patients with severe eosinophilic asthma (SEA) and comorbid chronic rhinosinusitis with NP are limited. The objective of this study was to assess NP and asthma outcomes in benralizumab-treated patients with SEA and comorbid NP in a real-world setting. PATIENTS AND METHODS: RANS was a retrospective, multi-country observational study (ClinicalTrials.gov: NCT05180357) using medical chart reviews of adults with SEA and comorbid NP...
2024: Journal of Asthma and Allergy
#6
JOURNAL ARTICLE
Sarah Onuora
No abstract text is available yet for this article.
April 9, 2024: Nature Reviews. Rheumatology
#7
JOURNAL ARTICLE
Charlene Desaintjean, Kaïs Ahmad, Julie Traclet, Mathieu Gerfaud-Valentin, Cecile-Audrey Durel, Jean-Charles Glerant, Arnaud Hot, François Lestelle, Sabine Mainbourg, Mouhamad Nasser, Pascal Seve, Ségolène Turquier, Gilles Devouassoux, Vincent Cottin
INTRODUCTION: Asthma associated with eosinophilic granulomatosis with polyangiitis (EGPA) is often severe and corticosteroid-dependent, leading to significant morbidity. Mepolizumab and benralizumab are humanized monoclonal antibodies targeting interleukin 5 (IL-5) and its receptor, respectively. They have been shown to be effective in steroid-sparing in patients with severe eosinophilic asthma. OBJECTIVE: Our aim was to evaluate the efficacy and safety of mepolizumab and benralizumab prescribed for severe asthma in patients with EGPA under "real-world" conditions...
2024: Frontiers in Medicine
#8
JOURNAL ARTICLE
David J Jackson, Girolamo Pelaia, Benjamin Emmanuel, Trung N Tran, David Cohen, Vivian H Shih, Anat Shavit, Douglas Arbetter, Rohit Katial, Adrian Paul J Rabe, Esther Garcia Gil, Marisa Pardal, Javier Nuevo, Michael Watt, Silvia Boarino, Sheena Kayaniyil, Cláudia Chaves Loureiro, Alicia Padilla-Galo, Parameswaran Nair
BACKGROUND: Pivotal Phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection. METHODS: XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA...
April 4, 2024: European Respiratory Journal
#9
JOURNAL ARTICLE
Kefang Lai, Dejun Sun, Ranran Dai, Ronnie Samoro, Hae-Sim Park, Annika Åstrand, David Cohen, Maria Jison, Vivian H Shih, Viktoria Werkström, Yuhui Yao, Yajuan Zhang, Wenying Zheng, Nanshan Zhong, Albay Albert, Bo Jianping, Chen Bi, Chen Lijun, Chen Mei, Chen Min, Chen Ping, Chen Zhimin, Chian Chih-Feng, Cho You Sook, Fu Xiuhua, Gao Xiwen, Gu Wei, Han Wei, Han Zhihai, Hu Xi Wei, Huang Kewu, Huang Mao, Isidro Marie Grace Dawn, Jeong Inbeom, Jiang Luning, Jiang Mingyan, Jiang Shanping, Jin Meiling, Kang Jian, Kim Jin Woo, Kim Sang-Ha, Kuang Jiulong, Kuo Ping-Hung, Li Jie, Li Manxiang, Li Minjing, Li Ruoran, Li Wen, Li Xianhua, Li Yanming, Lim Seong Yong, Liu Chuanhe, Liu Chuntao, Liu Jing, Liu Xiaoxia, Lu Huiyu, Luo Zhuang, Ma Shengxi, Mao Liangping, Min Kyung Hoon, Mu Lin, Park Choon-Sik, Park Hae Sim, Park Hye-Kyung, Park Jung-Won, Perng Diahn-Warng, Samoro Ronnie, Shi Guochao, Sun Debin, Sun Dejun, Wang Chun-Hua, Wang Guangfa, Wang Limin, Wang Xuefen, Wang Yan, Wei Liping, Wu Haihong, Xiao Yi, Xiao Zuke, Xie Canmao, Xu Jin-Fu, Xu Xingxiang, Xu Xiyuan, Yan Jianping, Yang Hongzhong, Yoon Ho Joo, Yu Wencheng, Zhang Jin, Zhang Longju, Zhang Min, Zhang Wei, Zhao Jianping, Zhao Ziwen, Zhu Xiaoli, Zhu Yingqun
BACKGROUND: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. OBJECTIVE: To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. METHODS: MIRACLE (NCT03186209) was a randomized, Phase 3 study in China, South Korea, and the Philippines. Patients aged 12-75 years with severe asthma receiving medium-to-high-dose inhaled corticosteroid/long-acting β2 -agonists, stratified (2:1) by baseline blood eosinophil count (bEOS) (≥300/μL; <300/μL), were randomized (1:1) to benralizumab 30 mg or placebo...
April 1, 2024: Respiratory Medicine
#10
JOURNAL ARTICLE
Antonio Nieto-García, María Nieto-Cid, Ángel Mazón-Ramos
PURPOSE OF REVIEW: The aim is to update the information currently available for the use of biologics in severe asthma in children, in order to facilitate their prescription as far as possible. RECENT FINDINGS: The appearance of biologics for the treatment of severe asthma has meant a revolutionary change in the therapeutic approach to this disease. Currently, five biologics have been approved for severe asthma in children and/or adolescents by the regulatory agencies: omalizumab, mepolizumab, benralizumab, dupilumab and tezepelumab...
April 2, 2024: Current Opinion in Allergy and Clinical Immunology
#11
JOURNAL ARTICLE
Paolo Cameli, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Maria D'Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Marco Benci, Silvia Boarino, Francesco Menzella
PURPOSE: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching biologic treatment is a strategy adopted to optimize asthma control when patients show partial or no response to previous biologics. PATIENTS AND METHODS: ANANKE is a retrospective, multicenter Italian study (NCT04272463). Here, we outline the characteristics and long-term clinical outcomes in naïve-to-biologics and biologics-experienced patients treated with benralizumab for up to 96 weeks...
2024: Journal of Asthma and Allergy
#12
RANDOMIZED CONTROLLED TRIAL
Matthew B Stanbrook
Jackson DJ, Heaney LG, Humbert M, et al; SHAMAL Investigators. Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study. Lancet. 2024;403:271-281. 38071986.
April 2024: Annals of Internal Medicine
#13
JOURNAL ARTICLE
William Shomali, Jason Gotlib
DISEASE OVERVIEW: The eosinophilias encompass a broad range of non-hematologic (secondary or reactive) and hematologic (primary or clonal) disorders with the potential for end-organ damage. DIAGNOSIS: Hypereosinophilia (HE) has generally been defined as a peripheral blood eosinophil count greater than 1.5 × 109 /L, and may be associated with tissue damage. After the exclusion of secondary causes of eosinophilia, diagnostic evaluation of primary eosinophilias relies on a combination of various tests...
March 29, 2024: American Journal of Hematology
#14
REVIEW
Felix Klimek, Christoph Bergmann, Jan Hagemann, Mandy Cuevas, Sven Becker, Oliver Pfaar, Ingrid Casper, Ludger Klimek
INTRODUCTION: Eosinophils play an important regulatory and immunomodulatory role in airway mucosa and have antiparasitic and antiviral properties as well as pro-inflammatory effects that may also cause persistence of inflammation with tissue remodeling. The number of eosinophils and the detection of specific mediators in biological samples from, e.g., blood, nasal secretions, and bronchial fluid can serve as biomarkers that reflect the underlying pathophysiology of certain diseases, predict treatment success, and detect therapy effects...
2024: Allergologie Select
#15
JOURNAL ARTICLE
Giada Sambugaro, Elena Brambilla, Giulia Costanzo, Vera Bonato, Andrea Giovanni Ledda, Stefano Del Giacco, Riccardo Scarpa, Marcello Rattazzi, Elisabetta Favero, Francesco Cinetto, Davide Firinu
This is a multicentric investigation involving two Italian centers that examined the clinical course of COVID-19 in patients receiving biological therapy targeting type 2 inflammation and those not receiving biologicals. Since the beginning of the COVID-19 pandemic, the management of respiratory and allergic disorders and the potential impact of biological therapy in the most severe forms has been a point of uncertainty. Our multicentric investigation aimed to compare the clinical course of COVID-19 and the impact of vaccination in an Italian cohort of patients with atopic disorders caused by a type 2 inflammation, such as eosinophilic asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), atopic dermatitis (AD), and chronic spontaneous urticaria (CSU)...
March 13, 2024: Life
#16
Bianca Oprescu, Oana Raduna, Stefan Mihaicuta, Stefan Frent
Background and Objectives : Severe adult-onset eosinophilic asthma and COPD with eosinophilic inflammation are two entities with a similar clinical course and are sometimes difficult to differentiate in clinical practice, especially in patients with a history of smoking. Anti-IL-5 or -IL-5R biological therapy has been shown to be highly effective in severe eosinophilic asthma but has not demonstrated significant benefit in patients with COPD with the eosinophilic phenotype. Our aim was to illustrate this issue in the form of a case report...
February 25, 2024: Medicina
#17
JOURNAL ARTICLE
Eva Martinez-Moragon, Eusebi Chiner, Alexandra Suliana Mogrovejo, Marta Palop Cervera, Inmaculada Lluch Tortajada, Ignacio Boira Enrique, Andrés Fernando Sánchez Vera
Patients with severe eosinophilic asthma experience high risk of exacerbations and reduced quality of life. Benralizumab, a monoclonal antibody binding to IL-5 receptor α subunit, is an approved drug for its treatment. The objective was to describe clinical remission after benralizumab prescription in routine clinical practice. Retrospective multicenter study with data from four hospitals in Valencian Community (Spain) with asthma units between 2019 and 2020. Data was gathered at baseline and after 12 months...
March 23, 2024: Journal of Asthma
#18
JOURNAL ARTICLE
Moritz Z Kayser, Hendrik Suhling, Jan Fuge, Christopher A Hinze, Nora Drick, Nikolaus Kneidinger, Jürgen Behr, Christian Taube, Tobias Welte, Ina Haasler, Katrin Milger
BACKGROUND: Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. While all biologics are efficient individually, the choice of biologic is complicated by insufficient data on their comparative long-term treatment efficacy. Here, we compare the real-life efficacy of these biologics in asthma therapy over 12 months...
March 21, 2024: BMC Pulmonary Medicine
#19
JOURNAL ARTICLE
Clare Bolton, Tim Harrison, Njira Lugogo, Anne Fuhlbrigge, Ian Hirsch, Thomas Bengtsson, Stefan Peterson, Martin Sidaway, Esther Garcia Gil, Malin Fagerås, Carla A Da Silva
BACKGROUND: CompEx Asthma, a composite end-point for asthma exacerbations, captures clinically relevant, diary-based acute worsening events (AWEs) (defined as deterioration in daily peak expiratory flow concurrent with deterioration in asthma symptoms and/or rescue therapy use) and severe exacerbations (SevEx) (defined by American Thoracic Society/European Respiratory Society guidelines). We hypothesised that CompEx and SevEx would show similar benralizumab treatment effects and correlations to blood eosinophil counts in patients with severe asthma...
March 2024: ERJ Open Research
#20
JOURNAL ARTICLE
H James Wedner, Takao Fujisawa, Theresa W Guilbert, Masanori Ikeda, Vinay Mehta, Jonathan S Tam, Pradeep B Lukka, Sara Asimus, Tomasz Durżyński, James Johnston, Wendy I White, Mihir Shah, Viktoria Werkström, Maria L Jison
BACKGROUND: Benralizumab is an anti-interleukin-5 receptor α monoclonal antibody approved as an add-on maintenance treatment for patients with uncontrolled severe asthma. Prior Phase 3 studies have evaluated benralizumab in patients aged ≥12 years with severe uncontrolled asthma. The TATE study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), and safety of benralizumab treatment in children. METHODS: TATE was an open-label, Phase 3 study of benralizumab in children aged 6-11 years from the United States and Japan (plus participants aged 12-14 years from Japan) with severe eosinophilic asthma...
March 2024: Pediatric Allergy and Immunology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
